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Summary
Background Analysis of primary healthcare datasets offers the
possibility to increase understanding of the epidemiology of acute
uncommon conditions such as anaphylaxis, but these datasets remain
under-exploited.
Aim To investigate recent trends in the recorded incidence, lifetime
prevalence and prescribing of adrenaline for anaphylaxis in England.
Methods QRESEARCH is one of the world’s largest national aggregated
health databases containing the records of over nine million patients.We
extracted data on all patients with a recorded diagnosis of anaphylaxis and
calculated annual age-sex standardized incidence and lifetime period
prevalence rates for each year from 2001–2005.We also analysed trends in
adrenaline prescribing in those with a recorded diagnosis of anaphylaxis.
National population figures were used to estimate numbers of people in
England that have experienced anaphylaxis at some point in their lives.
Results The age-sex standardized incidence of anaphylaxis was 6.7 per
100,000 person-years in 2001 and increased by 19% to 7.9 in 2005. Lifetime
age-sex standardized prevalence of a recorded diagnosis of anaphylaxis was
50.0 per 100,000 in 2001 and increased by 51% to 75.5 in 2005. Prescribing of
adrenaline increased by 97% over this period. By the end of 2005 there were
an estimated 37,800 people that had experienced anaphylaxis at some point
in their lives.
Conclusions Recorded incidence, lifetime prevalence and prescribing of
adrenaline for anaphylaxis all showed substantial increases in recent years.
An estimated 1 in 1,333 of the English population have at some point in their
lives experienced anaphylaxis.
Introduction
The American College of Allergy, Asthma and
Immunology Epidemiology Working Group on
Anaphylaxis recent international literature
review highlighted the substantial gaps in our
understanding of the epidemiology of anaphy-
laxis, noting that: ‘An improved epidemiologic
understanding of this disorder would aid ongoing
efforts to reduce morbidity and mortality from
anaphylaxis and could provide important clues for
primary prevention.’1 Particularly important are
gaps in relation to describing the actual numbers of
people at high risk of experiencing anaphylaxis,
disease trends over time and identifying those at
greatest risk of severe outcomes. Challenges
to answering these questions include the inherent
difficulties of mounting serial cross-sectional and
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prospective cohort studies of acute, short-lived
and uncommon conditions such as anaphylaxis.2
In the absence of such population-based studies,
exploitation of large national healthcare datasets,
with their key strengths of large numbers and rep-
resentative data, offers an important opportunity to
develop insights into the epidemiology of anaphy-
laxis.3 Work from England studying hospital admis-
sions for anaphylaxis has, for example, found rapid
and sustained increases in the numbers of hospital
admissions for anaphylaxis over the last decade,
these data suggesting an underlying increase in the
incidence of anaphylaxis.4–8
There are, however, important inherent limita-
tions associated with extrapolating population
estimates from hospital admission data in the case
of anaphylaxis, as it seems likely that only aminor-
ity of those experiencing anaphylaxis in England
are actually admitted as in-patients. Evidence sug-
gests that the majority of cases of anaphylaxis are
sent home from accident and emergency depart-
ments.9 Understanding how the epidemiology of
anaphylaxis may be changing is also potentially
problematic because of the risk of changing admis-
sion thresholds affecting findings. There has, fur-
thermore, been the additional challenge posed by
the fact that, until recently, English hospital data at
national level have only provided measures of ad-
mission episodes rather than numbers of individ-
ual patients admitted, thereby rendering it
impossible to assess the impact of repeated admis-
sions of the same individual.8
Studying primary care databases, which are
more likely to reflect the overall population picture
of anaphylaxis than hospital in-patient episode
data, should help to overcome some of these limi-
tations. Building on our previous work using hos-
pital datasets,4–8 we sought to describe trends in
recorded diagnosis of anaphylaxis and prescribing
for anaphylaxis in England during the five-year
period between 1 January 2001 and 31 December
2005. Future planned work will seek to identify
those at greatest risk of poor outcomes.
Methods
We used Version 10 of the QRESEARCH database,
which is a very large nationally representative
anonymized aggregated health dataset derived
from 525 general practices throughout the UK.10 It
contains data on over 30 million patient years of
observation, these being derived from over nine
million individual patients.
General practices were included in the analysis
if they were based in England, were using the
Egton Medical Information Systems (EMIS) soft-
ware and had transmitted complete data to the
central QRESEARCH repository for the period
from 1 January 1999 to 31 December 2005. This
stipulation for practices to be submitting data for a
full two years prior to our period of interest was to
ensure that practices had sufficient lead time to
become accustomed to using their computing
systems for routine work.
Four hundred and twenty-two (80%) of the
QRESEARCH practices had complete data for
England for the seven-year period in question
(1999–2005), these practices yielding a total of
2,958,366 patients. Contributing practices were
distributed throughout England and had an age-
sex structure that was found to be directly compar-
able to the age-sex structure of the English
population (data not shown).
Patients were included in the analysis year if
they were registered for the entire analysis year in
question. Patients who might have incomplete
data (i.e. temporary residents, newly registered
patients and those who joined, left or died
during the year) were therefore not eligible for
inclusion.
We considered patients to have anaphylaxis if
they had a computer-recorded diagnostic Read
code for anaphylaxis in their electronic health
record for the relevant time period.
Incidence was defined as the number of new cases
of disease diagnosed in a specific year, with the
denominator of number of patient years of obser-
vation (this being calculated as a product of the
number of patients registered with practices and
their length of registration) being used to calculate
incidence rates. Lifetime prevalence was defined as
the numbers of people with a diagnosis of anaphy-
laxis recorded in the GP records on at least one
occasion at any point in their lives; the denominator
used to calculate the lifetime prevalence rate was
the number of patients registered with the study
practices.
Because of the knownage and sex variations,we
standardized rates by sex and five-year age bands
using the estimatedmid-year population estimates
for England in each year as our reference popu-
lation. These results were then scaled up to
estimate the actual numbers of people with ana-
phylaxis in England. In order to better estimate the
actual numbers of people affected by anaphylaxis,
we calculated 95% confidence intervals around
these estimates of lifetime prevalence and absolute
numbers of people affected in 2005.11
In order to describe trends in prescribing of
self-administered adrenaline, we extracted linked
review of services
for allergy.
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prescribing data in those with a recorded diagno-
sis of anaphylaxis and estimated numbers of
prescriptions prescribed (which may or may not
equate with the numbers of prescriptions dis-
pensed) nationally for each of the five years.
Results
Age-sex standardization of rates
Figure 1 reveals how the lifetime prevalence of
anaphylaxis varied very markedly by age and sex.
In the pre-pubertal period, lifetime prevalencewas
highest inmales, but then increased very rapidly in
females, peaking during the fifth decade. These
findings underscore the importance of age-sex
standardization of data.
Incidence rate of anaphylaxis and changes
over time
Table 1 details the incidence rate of anaphylaxis for
each of the five years of interest, these data show-
ing an overall 19% increase during the period
2001–2005.
Lifetime prevalence rate of anaphylaxis
and changes over time
Table 2 details the age-sex standardized lifetime
prevalence rate of anaphylaxis for each of the five
years of interest, these data revealing a 51%
increase in recorded lifetime prevalence of
anaphylaxis over this time period.
Trends in adrenaline prescribing
Table 3 details the estimated numbers of commu-
nity prescriptions in patients with anaphylaxis
throughout England for each of the five years,
these revealing a 97% increase in prescribing of
adrenaline over the study period.
Numbers of people with a history of
anaphylaxis
The estimated numbers of people who have had
anaphylaxis at some point in their lives increased
from 24,700 (95%CI 23,500–26,000) in 2001 to
37,800 (95% CI 36,300–39,400), this 2005 estimate
indicating that 1 in 1,333 of the English population
had a lifetime prevalence of anaphylaxis.
Discussion
There has been a marked recent increase in
recorded incidence and lifetime prevalence of ana-
phylaxis and prescribing of adrenaline in these
patients.
Considering findings in relation to the
published literature
The age-sex variations described in Figure 1 are in
keeping with described patterns showing an inter-
action between age and gender.1,12 The American
College of Allergy, Asthma and Immunology
Epidemiology Working Group on Anaphylaxis
found that the reported lifetime frequency of ana-
phylaxis varies internationally between 0.02–0.5%
and our estimate of 75.5 per 100,000 or 0.08% in
2005 is comparable to these data.1 These esti-
Figure 1
Age-sex variations in lifetime prevalence of anaphylaxis per
100,000 registered patients for 2001 and 2005
Table 1
Incidence rate of anaphylaxis per 100,000
patient-years, 2001–2005
Year Age-sex standardized
incidence rate/100,000
person-years
95% CI
2001 6.7 5.7–7.7
2002 6.6 5.7–7.6
2003 6.8 5.9–7.9
2004 8.5 7.5–9.6
2005 7.9 7.0–9.0
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mates are furthermore very comparable to the
limited available data from other primary care
datasets.13,14
Main strengths and limitations of this work
The main strengths of this study include our interro-
gation of an extremely large nationally representative
dataset, the fact that all contributing practices used
the same computing systems for electronically re-
cording clinical data and the approach used to ensure
that all contributing practices were accustomed to
electronically recording routine data. The study de-
signmeans that it was not subject to selection bias due
to non-responders or recall bias. As recommended by
the American College of Allergy, Asthma and Immu-
nology Epidemiology Working Group on Anaphy-
laxis,1 our attempt to obtain various estimates of
disease frequency is allowing a comprehensive pic-
ture of the epidemiology of anaphylaxis in England to
emerge.4–8
There are a number of limitations that need to
be considered when using databases of routinely
collected data and these all potentially apply to
this work. Most importantly, we were dependant
on physician-recorded diagnosis of anaphylaxis
and there may have been improvements in ana-
phylaxis recording over this time period. The rela-
tively short time window over which trends were
studied is another limitation, but this does also
have the advantage of confining analysis to a
period during which there were no changes in
disease definition or classification.
Conclusions and implications for future
research
This large national study reveals that the recorded
incidence and lifetime prevalence of anaphylaxis
increased in England during the first half of this
decade. Further work is now needed to explore
why these increases occurred and determine
which of the increasing numbers of individuals
with a history of anaphylaxis are at greatest risk
of recurrent anaphylaxis and severe outcomes
should a further episode occur.15 The changes in
disease patterns described highlight the need
for ongoing surveillance of the epidemiology of
anaphylaxis.
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